At the news
? BULLISHIMPACT 7/10 8-K filed Apr 17, 2026 at 16:15 ET
Theriva Biologics announced positive results from its VIRAGE Phase 2b clinical trial, showing improved overall survival and progression-free survival in metastatic pancreatic cancer patients treated with VCN-01 plus chemotherapy. The data, to be presented at the AACR 2026 meeting, supports an immune-mediated mechanism of action and demonstrates consistent benefits across subgroups, including those with liver metastases.
- Patients receiving VCN-01 + chemotherapy had improved overall survival (OS) and progression-free survival (PFS) compared to chemotherapy alone.
- The survival benefit was maintained across subgroups, including patients with liver metastases.
- Patients who received a second dose of VCN-01 showed a greater benefit in OS and PFS.
- The company has achieved alignment with both the FDA and EMA on a proposed pivotal Phase 3 trial.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access